Gerard G Hanna

Prof. Gerard G Hanna

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Radiotherapy and Oncology
Verified
Journal Article
Open access
TKTom Konert
Tom Konert
WVWouter Vogel
Wouter Vogel
MMMichael MacManus
Michael MacManus
UNUrsula Nestle
Ursula Nestle
JBJosé Belderbos
José Belderbos
GHGerard G Hanna
Gerard G Hanna
This document describes best practice and evidence based recommendations for the use of FDG-PET/CT for the purposes of radiotherapy target volume delineation (TVD) for curative intent treatment of non-small cell lung cancer (NSCLC). These recommendations have been written by an expert advisory group, convened by the International Atomic Energy Agency (IAEA) to facilitate a Coordinated Research Project (CRP) aiming to improve the applications of PET based radiation treatment planning (RTP) in low and middle income countries. These guidelines can be applied in routine clinical practice of radiotherapy TVD, for NSCLC patients treated with concurrent chemoradiation or radiotherapy alone, where FDG is used, and where a calibrated PET camera system equipped for RTP patient positioning is available. Recommendations are provided for PET and CT image visualization and interpretation, and for tumor delineation using planning CT with and without breathing motion compensation.

1 September 2010 in Clinical Oncology
Verified
Journal Article
Closed access
GHGerard G Hanna
Gerard G Hanna
AHA.R. Hounsell
A.R. Hounsell
JOJ.M. O’sUllivan
J.M. O’sUllivan

1 February 2014 in Clinical Oncology
Verified
Journal Article
Closed access
ACA.J. Cole
A.J. Cole
GHGerard G Hanna
Gerard G Hanna
SJS. Jain
S. Jain
JOJ.M. O'Sullivan
J.M. O'Sullivan

17 April 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
JCJohn Conibear
John Conibear
BCBrendan Chia
Brendan Chia
YNYenting Ngai
Yenting Ngai
ABAndrew Tom Bates
Andrew Tom Bates
NCNicholas Counsell
Nicholas Counsell
DLDavid Landau
David Landau
Introduction Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS. Methods and analysis SARON is a large, randomised controlled, multicentre, phase III trial for patients with oligometastatic EGFR, ALK and ROS1 mutation negative NSCLC (1–3 sites of synchronous metastatic disease, one of which must be extracranial). 340 patients will be recruited over 3 years from approximately 30 UK sites and randomised to receive either standard platinum-doublet chemotherapy only (control arm) or standard chemotherapy followed by RRT/SABR to their primary tumour and then SABR/SRS to all other metastatic sites (investigational arm). The primary endpoint is OS; the study is powered to detect an improvement in median survival from 9.9 months in the control arm to 14.3 months in the investigational arm with 85% power and two-sided 5% significance level. The secondary endpoints are LC, progression-free survival, new distant metastasis-free survival, toxicity and quality of life. An early feasibility review will take place after 50 randomised patients. Patients requiring both conventional thoracic RT to the primary and SABR to a thoracic metastasis will be included in a thoracic SABR safety substudy to assess toxicity and planning issues in this subgroup of patients more thoroughly. Ethics and dissemination All participants are given a SARON patient information sheet and required to give written informed consent. Results will be submitted for presentation at local and international conferences and expected to be published in a peer-reviewed journal. Trial registration number NCT02417662. Sponsor reference UCL/13/0594.

17 February 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
PMPatrick Murray
Patrick Murray
KFKevin Franks
Kevin Franks
GHGerard G Hanna
Gerard G Hanna
Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.

1 July 2010 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
IDIris E. van Dam
Iris E. van Dam
JKJohn R. van Sörnsen de Koste
John R. van Sörnsen de Koste
GHGerard G Hanna
Gerard G Hanna
RMRebecca Muirhead
Rebecca Muirhead
BSBen J. Slotman
Ben J. Slotman
SSSuresh Senan
Suresh Senan